PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
22363534-0	2012	An N-ethyl-N-nitrosourea (ENU)-induced dominant negative mutation in the JAK3 kinase protects against cerebral malaria.	Ethylnitrosourea	3-24	Janus kinase 3	Mus musculus	73-77
22252297-3	2012	Recently, CP-690,550 (tofacitinib), originally developed as a JAK3 inhibitor, has been shown to be effective in phase III clinical trials of rheumatoid arthritis and collagen-induced arthritis (CIA) models, but the precise mechanism of the effect, especially with respect to Th17 cells, is poorly understood.	tofacitinib	10-16	Janus kinase 3	Mus musculus	62-66
22252297-3	2012	Recently, CP-690,550 (tofacitinib), originally developed as a JAK3 inhibitor, has been shown to be effective in phase III clinical trials of rheumatoid arthritis and collagen-induced arthritis (CIA) models, but the precise mechanism of the effect, especially with respect to Th17 cells, is poorly understood.	tofacitinib	22-33	Janus kinase 3	Mus musculus	62-66
22829185-2	2011	Our novel JAK2 inhibitor, NS-018, was highly active against JAK2 with a 50% inhibition (IC(50)) of <1 n, and had 30-50-fold greater selectivity for JAK2 over other JAK-family kinases, such as JAK1, JAK3 and tyrosine kinase 2.	NS-018	26-32	Janus kinase 3	Mus musculus	201-205
21443863-5	2011	IL-2-induced phosphorylation of STAT5A and JAK3, but not JAK1, was diminished in the presence of curcumin, indicating inhibition of critical proximal events in IL-2R signaling.	Curcumin	97-105	Janus kinase 3	Mus musculus	43-47
19836234-1	2009	A novel class of Janus tyrosine kinase 3 (JAK3) inhibitors based on a 2-benzimidazoylpurinone core structure is described.	2-benzimidazoylpurinone	70-93	Janus kinase 3	Mus musculus	42-46
21691072-7	2011	As a result, JAK3 was expressed in erythrocytes and phosphorylated following 24h and 48h glucose depletion.	Glucose	89-96	Janus kinase 3	Mus musculus	13-17
21691072-11	2011	Glucose depletion increased annexin V binding, an effect significantly blunted in jak3(-/-) erythrocytes and in the presence of the JAK3 inhibitors.	Glucose	0-7	Janus kinase 3	Mus musculus	82-86
21691072-11	2011	Glucose depletion increased annexin V binding, an effect significantly blunted in jak3(-/-) erythrocytes and in the presence of the JAK3 inhibitors.	Glucose	0-7	Janus kinase 3	Mus musculus	132-136
19836234-0	2009	2-Benzimidazolyl-9-(chroman-4-yl)-purinone derivatives as JAK3 inhibitors.	2-benzimidazolyl-9-(chroman-4-yl)-purinone	0-42	Janus kinase 3	Mus musculus	58-62
21393628-5	2011	Importantly, the selective JAK3 inhibitor CP-690,550 blocked the phosphorylation and the nuclear translocation of STAT5 following treatment of cells with IL-2 but not with IL-3.	tofacitinib	42-48	Janus kinase 3	Mus musculus	27-31
20506481-2	2010	We undertook this study to determine whether the JAK-3 selective inhibitor WYE-151650 would be sufficient to disrupt cytokine signaling and to ameliorate autoimmune disease pathology without inhibiting other pathways mediated by JAK-1, JAK-2, and Tyk-2.	wye-151650	75-85	Janus kinase 3	Mus musculus	49-54
20486473-0	2010	Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF receptor kinase.	WHI P131	94-102	Janus kinase 3	Mus musculus	133-171
19836234-1	2009	A novel class of Janus tyrosine kinase 3 (JAK3) inhibitors based on a 2-benzimidazoylpurinone core structure is described.	2-benzimidazoylpurinone	70-93	Janus kinase 3	Mus musculus	17-40
18094329-1	2008	PF-956980 is a selective inhibitor of JAK3, related in structure to CP-690550, a compound being evaluated in clinical trials for rheumatoid arthritis and prevention of allograft rejection.	tofacitinib	68-77	Janus kinase 3	Mus musculus	38-42
19427203-0	2009	Synthetic staurosporines via a ring closing metathesis strategy as potent JAK3 inhibitors and modulators of allergic responses.	Staurosporine	10-24	Janus kinase 3	Mus musculus	74-78
19427203-1	2009	The synthesis and biological evaluation of JAK3 based staurosporine compounds is described.	Staurosporine	54-67	Janus kinase 3	Mus musculus	43-47
19181385-9	2009	GANP down-regulates JAK1/JAK3 to STAT6-signaling with regulation of arginine methylation activity, which might be responsible for the B cell endogenous suppressive mechanism of hyper-IgE.	Arginine	68-76	Janus kinase 3	Mus musculus	25-29
18242596-0	2008	The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia.	tofacitinib	20-29	Janus kinase 3	Mus musculus	4-9
18242596-2	2008	The current study describes the immunosuppressive effects of CP-690550, a novel, small molecule inhibitor of JAK-3, in a murine model of allergic pulmonary inflammation.	tofacitinib	61-70	Janus kinase 3	Mus musculus	109-114
19596999-5	2009	In this study, we treated mice with established skin disease with R348, a small molecule inhibitor of JAK3, and observed a marked attenuation of skin lesions following 6 wk of treatment.	3-Ethyl-4-methylpyridine	66-70	Janus kinase 3	Mus musculus	102-106
18094329-1	2008	PF-956980 is a selective inhibitor of JAK3, related in structure to CP-690550, a compound being evaluated in clinical trials for rheumatoid arthritis and prevention of allograft rejection.	PF 956980	0-9	Janus kinase 3	Mus musculus	38-42
17688077-6	2007	In contrast, Compound DDE24, a synthetically activated genistein, an inhibitor of Epidermal Growth Factor receptor (EGF-R), cellular homologue of oncogene product from Raus Avian sarcoma virus (SRC) and Syk tyrosine kinases, which Thus, selective targeting of JAK3 was highly effective in preventing development of intestinal tumors in Min mice resulting in markedly improved survival outcomes.	dde24	22-27	Janus kinase 3	Mus musculus	260-264
17541402-2	2007	We developed TG101209, an orally bioavailable small molecule that potently inhibits JAK2 (IC(50)=6 nM), FLT3 (IC(50)=25 nM) and RET (IC(50)=17 nM) kinases, with significantly less activity against other tyrosine kinases including JAK3 (IC(50)=169 nM).	TG101209	13-21	Janus kinase 3	Mus musculus	230-234
17234744-4	2007	Accordingly, methylprednisolone inhibited Tyr phosphorylation of STAT1, STAT3, and STAT5 in IL-2-cultured NK cells but only marginally in IL-15-cultured NK cells, whereas JAK3 was inhibited under both conditions.	Tyrosine	42-45	Janus kinase 3	Mus musculus	171-175
17688077-6	2007	In contrast, Compound DDE24, a synthetically activated genistein, an inhibitor of Epidermal Growth Factor receptor (EGF-R), cellular homologue of oncogene product from Raus Avian sarcoma virus (SRC) and Syk tyrosine kinases, which Thus, selective targeting of JAK3 was highly effective in preventing development of intestinal tumors in Min mice resulting in markedly improved survival outcomes.	Genistein	55-64	Janus kinase 3	Mus musculus	260-264
15869881-2	2005	The tyrphostin molecule AG490 inhibits the action of the janus kinases JAK2 and JAK3.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	24-29	Janus kinase 3	Mus musculus	80-84
16170336-4	2005	We also show that the STAT3 tyrosine phosphorylation is mediated in the malignant T cells by NPM/ALK independently of Jak3 kinase as evidenced by the presence of STAT3 phosphorylation in the NPM/ALK-transfected BaF3 cells that do not express detectable Jak3 and in the NPM/ALK-positive malignant T cells with either Jak3 activity impaired by a pan-Jak or Jak3-selective inhibitor or Jak3 expression abrogated by Jak3 siRNA.	Tyrosine	28-36	Janus kinase 3	Mus musculus	253-257
16170336-4	2005	We also show that the STAT3 tyrosine phosphorylation is mediated in the malignant T cells by NPM/ALK independently of Jak3 kinase as evidenced by the presence of STAT3 phosphorylation in the NPM/ALK-transfected BaF3 cells that do not express detectable Jak3 and in the NPM/ALK-positive malignant T cells with either Jak3 activity impaired by a pan-Jak or Jak3-selective inhibitor or Jak3 expression abrogated by Jak3 siRNA.	Tyrosine	28-36	Janus kinase 3	Mus musculus	253-257
16170336-4	2005	We also show that the STAT3 tyrosine phosphorylation is mediated in the malignant T cells by NPM/ALK independently of Jak3 kinase as evidenced by the presence of STAT3 phosphorylation in the NPM/ALK-transfected BaF3 cells that do not express detectable Jak3 and in the NPM/ALK-positive malignant T cells with either Jak3 activity impaired by a pan-Jak or Jak3-selective inhibitor or Jak3 expression abrogated by Jak3 siRNA.	Tyrosine	28-36	Janus kinase 3	Mus musculus	253-257
16170336-4	2005	We also show that the STAT3 tyrosine phosphorylation is mediated in the malignant T cells by NPM/ALK independently of Jak3 kinase as evidenced by the presence of STAT3 phosphorylation in the NPM/ALK-transfected BaF3 cells that do not express detectable Jak3 and in the NPM/ALK-positive malignant T cells with either Jak3 activity impaired by a pan-Jak or Jak3-selective inhibitor or Jak3 expression abrogated by Jak3 siRNA.	Tyrosine	28-36	Janus kinase 3	Mus musculus	253-257
16170336-4	2005	We also show that the STAT3 tyrosine phosphorylation is mediated in the malignant T cells by NPM/ALK independently of Jak3 kinase as evidenced by the presence of STAT3 phosphorylation in the NPM/ALK-transfected BaF3 cells that do not express detectable Jak3 and in the NPM/ALK-positive malignant T cells with either Jak3 activity impaired by a pan-Jak or Jak3-selective inhibitor or Jak3 expression abrogated by Jak3 siRNA.	Tyrosine	28-36	Janus kinase 3	Mus musculus	253-257
15852029-1	2005	We analyzed the effects of the Janus kinase 3 (Jak3)-specific inhibitor WHI-P131 (4-(4"-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline) and the Jak3/Syk inhibitor WHI-P154 (4-(3"-bromo-4"-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline) on the antigen-induced activation of mast cells.	WHI P131	72-80	Janus kinase 3	Mus musculus	31-45
15852029-1	2005	We analyzed the effects of the Janus kinase 3 (Jak3)-specific inhibitor WHI-P131 (4-(4"-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline) and the Jak3/Syk inhibitor WHI-P154 (4-(3"-bromo-4"-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline) on the antigen-induced activation of mast cells.	WHI P131	72-80	Janus kinase 3	Mus musculus	47-51
15852029-7	2005	In BMMCs from Jak3-/- mice, the antigen stimulation induced tyrosine phosphorylation of Fyn, which was inhibited by WHI-P131, as well as in BMMCs from wild-type mice and in RBL-2H3 cells.	Tyrosine	60-68	Janus kinase 3	Mus musculus	14-18
15869881-2	2005	The tyrphostin molecule AG490 inhibits the action of the janus kinases JAK2 and JAK3.	Tyrphostins	4-14	Janus kinase 3	Mus musculus	80-84
15671076-11	2005	A short IL-15 stimulation of TEC induced tyrosine phosphorylation of the main IL-15 signalling molecules (Jak-1, Jak-3, STAT-3 and STAT-5).	Tyrosine	41-49	Janus kinase 3	Mus musculus	113-118
11606024-9	2001	Tyrphostin is an inhibitor of Jak2, Jak3, STATI, STAT3 and STAT5.	Tyrphostins	0-10	Janus kinase 3	Mus musculus	36-40
15240680-3	2004	In this study, we show that adenosine suppressed IL-2-dependent proliferation of CTLL-2 T cells by inhibiting STAT5a/b tyrosine phosphorylation that is associated with IL-2R signaling without affecting IL-2-induced phosphorylation of Jak1 or Jak3.	Adenosine	28-37	Janus kinase 3	Mus musculus	242-246
14678034-0	2004	The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models.	tofacitinib	26-35	Janus kinase 3	Mus musculus	10-15
14678034-2	2004	The current study describes the immunosuppressive effects of CP-690550, a novel, small molecule inhibitor of JAK-3, in various murine models.	tofacitinib	61-70	Janus kinase 3	Mus musculus	109-114
14558439-2	2003	The JAK3 inhibitor 4-(4"-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (CAS 202475-60-3, JANEX-1, WHI-P131) prevented the rejection of islet allografts in mice with a normal JAK3 expression status.	WHI P131	19-70	Janus kinase 3	Mus musculus	4-8
14558439-2	2003	The JAK3 inhibitor 4-(4"-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (CAS 202475-60-3, JANEX-1, WHI-P131) prevented the rejection of islet allografts in mice with a normal JAK3 expression status.	WHI P131	19-70	Janus kinase 3	Mus musculus	174-178
12351382-3	2002	Our studies show that Jak3 is a primary response gene for granulocyte colony-stimulating factor (G-CSF) and the accumulation of tyrosine phosphorylated Jak3 correlated with cell growth inhibition and terminal granulocytic differentiation in response to G-CSF.	Tyrosine	128-136	Janus kinase 3	Mus musculus	22-26
12351382-3	2002	Our studies show that Jak3 is a primary response gene for granulocyte colony-stimulating factor (G-CSF) and the accumulation of tyrosine phosphorylated Jak3 correlated with cell growth inhibition and terminal granulocytic differentiation in response to G-CSF.	Tyrosine	128-136	Janus kinase 3	Mus musculus	152-156
12093291-9	2002	In addition, the specific JAK3 tyrosine kinase inhibitor WHI-P131 significantly reduced IL-21-induced proliferation of BaF3/IL-21R alpha cells.	WHI P131	57-65	Janus kinase 3	Mus musculus	26-30
14593182-2	2003	We report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.	tofacitinib	74-80	Janus kinase 3	Mus musculus	68-72
12389628-1	2002	Here we show that the Janus kinase 3 (JAK3) inhibitor 4-(3"-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-3) exhibits potent anti-GVHD activity and consequently improves the post-BMT survival outcome of C57BL/6 (H-2b) recipient mice transplanted with allogeneic bone marrow/splenocyte (BM/S) grafts from MHC disparate BALB/c mice (H-2d).	WHI P180	54-105	Janus kinase 3	Mus musculus	22-36
12389628-1	2002	Here we show that the Janus kinase 3 (JAK3) inhibitor 4-(3"-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-3) exhibits potent anti-GVHD activity and consequently improves the post-BMT survival outcome of C57BL/6 (H-2b) recipient mice transplanted with allogeneic bone marrow/splenocyte (BM/S) grafts from MHC disparate BALB/c mice (H-2d).	WHI P180	54-105	Janus kinase 3	Mus musculus	38-42
12389628-7	2002	The allografts from (Jak3-/-) C57BL/6 (H-2b) mice rescued MHC-disparate recipient BALB/c mice (H-2d) of the lethal toxicity of TBI without causing fatal GVHD.	Thioacetazone	127-130	Janus kinase 3	Mus musculus	21-25
12039914-1	2002	The distinct thiol redox status in macrophages, either elevated or reduced intracellular content of glutathione (GSH), was confirmed during aging in IL-2 receptor (IL-2R)gamma and Janus family tyrosine kinase (JAK)3 gene-disrupted mice.	Sulfhydryl Compounds	13-18	Janus kinase 3	Mus musculus	193-215
12039914-1	2002	The distinct thiol redox status in macrophages, either elevated or reduced intracellular content of glutathione (GSH), was confirmed during aging in IL-2 receptor (IL-2R)gamma and Janus family tyrosine kinase (JAK)3 gene-disrupted mice.	Glutathione	100-111	Janus kinase 3	Mus musculus	193-215
11304656-1	2001	WHI-P131 is a novel dimethoxyquinazoline compound that is a potent inhibitor of Janus kinase-3-(JAK3)-dependent mast cell responses.	WHI P131	0-8	Janus kinase 3	Mus musculus	96-100
11278899-2	2001	Treatment of platelets with thrombin induced tyrosine phosphorylation of the JAK3 target substrates STAT1 and STAT3.	Tyrosine	45-53	Janus kinase 3	Mus musculus	77-81
11278301-6	2001	In contrast, IL-2-induced tyrosine phosphorylation of the kinases Jak1 and Jak3 located upstream of STAT5 was not affected by UV.	Tyrosine	26-34	Janus kinase 3	Mus musculus	75-79
11304656-1	2001	WHI-P131 is a novel dimethoxyquinazoline compound that is a potent inhibitor of Janus kinase-3-(JAK3)-dependent mast cell responses.	2,4-dimethoxyquinazoline	20-40	Janus kinase 3	Mus musculus	96-100
11082424-1	2000	4-(3",5"-Dibromo-4"-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97) is a rationally designed potent inhibitor of Janus kinase (JAK)-3.	WHI P97	0-64	Janus kinase 3	Mus musculus	120-140
11082424-1	2000	4-(3",5"-Dibromo-4"-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97) is a rationally designed potent inhibitor of Janus kinase (JAK)-3.	WHI P97	66-73	Janus kinase 3	Mus musculus	120-140
10839803-7	2000	The generation of Th2 cells induced in vitro by anti-TCR stimulation was inhibited significantly by the presence of Jak3 antisense oligonucleotides, suggesting that the Jak3 upregulation is an important event for the Th2 cell development.	Oligonucleotides	131-147	Janus kinase 3	Mus musculus	116-120
11046040-3	2000	We recently reported that tyrphostin AG-490 selectively blocked IL-2 activation of Jak3/Stat5 and growth of murine T cell lines.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	26-43	Janus kinase 3	Mus musculus	83-87
10839803-7	2000	The generation of Th2 cells induced in vitro by anti-TCR stimulation was inhibited significantly by the presence of Jak3 antisense oligonucleotides, suggesting that the Jak3 upregulation is an important event for the Th2 cell development.	Oligonucleotides	131-147	Janus kinase 3	Mus musculus	169-173
10733938-2	2000	Results showed that one new homologue of myosin heavy chain, designated MAJN (molecule associated with Jak3 N-terminal), could bind to Jak3 in a tyrosine-phosphorylation-independent manner.	Tyrosine	145-153	Janus kinase 3	Mus musculus	103-107
10480916-4	1999	In vivo administration of the JAK3 inhibitor WHI-P131 prevented mast cell degranulation and development of cutaneous as well as systemic fatal anaphylaxis in mice at nontoxic dose levels.	WHI P131	45-53	Janus kinase 3	Mus musculus	30-34
10731717-8	2000	We also showed that the tyrosine phosphorylation of a Janus kinase, JAK3, is enhanced by IL-4 treatment, suggesting that the PGE(2)-mediated c-fos mRNA induction is inhibited by IL-4 through the tyrosine phosphorylation of JAK3.	Tyrosine	24-32	Janus kinase 3	Mus musculus	68-72
10731717-8	2000	We also showed that the tyrosine phosphorylation of a Janus kinase, JAK3, is enhanced by IL-4 treatment, suggesting that the PGE(2)-mediated c-fos mRNA induction is inhibited by IL-4 through the tyrosine phosphorylation of JAK3.	Tyrosine	24-32	Janus kinase 3	Mus musculus	223-227
10731717-8	2000	We also showed that the tyrosine phosphorylation of a Janus kinase, JAK3, is enhanced by IL-4 treatment, suggesting that the PGE(2)-mediated c-fos mRNA induction is inhibited by IL-4 through the tyrosine phosphorylation of JAK3.	Prostaglandins E	125-128	Janus kinase 3	Mus musculus	68-72
10731717-8	2000	We also showed that the tyrosine phosphorylation of a Janus kinase, JAK3, is enhanced by IL-4 treatment, suggesting that the PGE(2)-mediated c-fos mRNA induction is inhibited by IL-4 through the tyrosine phosphorylation of JAK3.	Prostaglandins E	125-128	Janus kinase 3	Mus musculus	223-227
10731717-8	2000	We also showed that the tyrosine phosphorylation of a Janus kinase, JAK3, is enhanced by IL-4 treatment, suggesting that the PGE(2)-mediated c-fos mRNA induction is inhibited by IL-4 through the tyrosine phosphorylation of JAK3.	Tyrosine	195-203	Janus kinase 3	Mus musculus	68-72
10731717-8	2000	We also showed that the tyrosine phosphorylation of a Janus kinase, JAK3, is enhanced by IL-4 treatment, suggesting that the PGE(2)-mediated c-fos mRNA induction is inhibited by IL-4 through the tyrosine phosphorylation of JAK3.	Tyrosine	195-203	Janus kinase 3	Mus musculus	223-227
9916733-0	1999	IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis.	Tyrosine	37-45	Janus kinase 3	Mus musculus	65-79
10421786-3	1999	However, disruption of a membrane-proximal proline-rich sequence motif ("box1") in either subunit of the bipartite IL-4R abolished not only ligand-induced tyrosine phosphorylation of Janus kinases JAK1 and JAK3, but also IL-4-triggered activation of STAT5 and concomitant cell proliferation.	Proline	43-50	Janus kinase 3	Mus musculus	206-210
9916733-6	1999	The stimulation with CD40L and/or IL-4 resulted in tyrosine phosphorylation of Janus kinase 3 (JAK3) in B cells, which was more strongly inducible in NC/Nga mice than in BALB/c mice.	Tyrosine	51-59	Janus kinase 3	Mus musculus	79-93
9916733-6	1999	The stimulation with CD40L and/or IL-4 resulted in tyrosine phosphorylation of Janus kinase 3 (JAK3) in B cells, which was more strongly inducible in NC/Nga mice than in BALB/c mice.	Tyrosine	51-59	Janus kinase 3	Mus musculus	95-99
7544789-3	1995	In addition to the activation of JAK1 and JAK3 tyrosine kinases, IL-9, unlike most hematopoietic cytokines but similar to IL-4, induces the tyrosine phosphorylation of a 170-kDa protein that is related to the insulin receptor substrate-1 (IRS-1).	Tyrosine	47-55	Janus kinase 3	Mus musculus	42-46
9218758-7	1997	We found that TGF-beta inhibited tyrosine phosphorylation of JAK1, JAK3, STAT3 and STAT5 in Con A blasts from NOD splenocytes and HT-2 cells.	Tyrosine	33-41	Janus kinase 3	Mus musculus	67-71
7657825-5	1995	Phosphotyrosine immunoprecipitation followed by Western blot analysis with a set of Jak kinase specific antibodies, identified p130 as Jak2 in the tax transformed mouse fibroblastic cell line and Jak3 in HTLV-1 transformed human T cell lines.	Phosphotyrosine	0-15	Janus kinase 3	Mus musculus	196-200
8605329-6	1996	Finally, our biochemical studies show that the JAK3 kinase domain, but not the pseudo-kinase domain, has tyrosine kinase activity and, furthermore, that JAK3 kinase activity is abolished by an amino acid substitution of the conserved lysine in the kinase domain (K851R).	Lysine	234-240	Janus kinase 3	Mus musculus	47-51
8605329-6	1996	Finally, our biochemical studies show that the JAK3 kinase domain, but not the pseudo-kinase domain, has tyrosine kinase activity and, furthermore, that JAK3 kinase activity is abolished by an amino acid substitution of the conserved lysine in the kinase domain (K851R).	Lysine	234-240	Janus kinase 3	Mus musculus	153-157
7489734-2	1995	The heterotrimeric complex of the mouse exogenous alpha and beta chains and the endogenous gamma chain on mouse lymphoid BW5147 cells showed the ability to bind IL-2 with high affinity, resulting in IL-2-induced tyrosine phosphorylation of a cytosolic tyrosine kinase, JAK3, which is involved in IL-2-dependent signals.	Tyrosine	212-220	Janus kinase 3	Mus musculus	269-273
7489741-2	1995	IL-7 was observed to induce a rapid and dose-dependent tyrosine phosphorylation of Jak 1 and Jak 3 and concomitantly, the tyrosine phosphorylation and DNA binding activity of multiple STAT proteins.	Tyrosine	55-63	Janus kinase 3	Mus musculus	93-98
7544789-5	1995	Cotransfection studies and in vitro experiments directly demonstrate that JAK1, JAK2, or JAK3 is capable of tyrosine phosphorylating IRS-1, suggesting a functional role for these kinases in vivo.	Tyrosine	108-116	Janus kinase 3	Mus musculus	89-93
34274356-4	2021	OBJECTIVE: Here we compared the effects of the JAK1/2 inhibitor baricitinib and the JAK3 inhibitor tofacitinib on eosinophil effector function in vitro and in vivo.	tofacitinib	99-110	Janus kinase 3	Mus musculus	84-88
33814980-7	2021	A selective Jak3 inhibitor CP-690550 (Xeljanz) approved by the FDA for certain chronic inflammatory conditions demonstrates immunosuppressive activity in rheumatoid arthritis, psoriasis, and organ transplant rejection.	tofacitinib	27-36	Janus kinase 3	Mus musculus	12-16
33814980-7	2021	A selective Jak3 inhibitor CP-690550 (Xeljanz) approved by the FDA for certain chronic inflammatory conditions demonstrates immunosuppressive activity in rheumatoid arthritis, psoriasis, and organ transplant rejection.	tofacitinib	38-45	Janus kinase 3	Mus musculus	12-16
34465864-6	2022	We subsequently found that Phf6 deficiency promotes JAK3M511I-induced T-ALL progression in mice by inhibiting the Bai1-Mdm2-P53 signaling pathway, which is independent of the JAK3/STAT5 signaling pathway.	phf6	27-31	Janus kinase 3	Mus musculus	52-56
34465864-7	2022	Furthermore, combination therapy with a JAK3 inhibitor (tofacitinib) and a MDM2 inhibitor (idasanutlin) reduces the Phf6 KO and JAK3M511I leukemia burden in vivo.	tofacitinib	56-67	Janus kinase 3	Mus musculus	40-44
34465864-7	2022	Furthermore, combination therapy with a JAK3 inhibitor (tofacitinib) and a MDM2 inhibitor (idasanutlin) reduces the Phf6 KO and JAK3M511I leukemia burden in vivo.	tofacitinib	56-67	Janus kinase 3	Mus musculus	128-132
34465864-7	2022	Furthermore, combination therapy with a JAK3 inhibitor (tofacitinib) and a MDM2 inhibitor (idasanutlin) reduces the Phf6 KO and JAK3M511I leukemia burden in vivo.	RG7388	91-102	Janus kinase 3	Mus musculus	40-44
34465864-7	2022	Furthermore, combination therapy with a JAK3 inhibitor (tofacitinib) and a MDM2 inhibitor (idasanutlin) reduces the Phf6 KO and JAK3M511I leukemia burden in vivo.	RG7388	91-102	Janus kinase 3	Mus musculus	128-132
34274356-10	2021	CONCLUSION: Our data suggest that the JAK1/2 inhibitor baricitinib is even more potent than the JAK3 inhibitor tofacitinib in suppressing eosinophil effector function.	tofacitinib	111-122	Janus kinase 3	Mus musculus	96-100
35192696-2	2022	During activation of Jak3, tyrosine residues are phosphorylated and potentially regulate its kinase activity.	Tyrosine	27-35	Janus kinase 3	Mus musculus	21-25
35192696-3	2022	We identified a novel tyrosine phosphorylation site within mouse Jak3, Y820, which is conserved in human Jak3, Y824.	Tyrosine	22-30	Janus kinase 3	Mus musculus	65-69
35192696-5	2022	Mutation of mouse Jak3 Y820 to alanine (Y820A) showed increased autophosphorylation of Jak3 and enhanced STAT5 tyrosine phosphorylation and transcriptional activation.	Alanine	31-38	Janus kinase 3	Mus musculus	87-91
35192696-5	2022	Mutation of mouse Jak3 Y820 to alanine (Y820A) showed increased autophosphorylation of Jak3 and enhanced STAT5 tyrosine phosphorylation and transcriptional activation.	Tyrosine	111-119	Janus kinase 3	Mus musculus	18-22
33980892-6	2021	Mice with a Cys905Ser knockin mutation in the endogenous JAK3 gene are viable and show no apparent welfare issues.	cys905ser	12-21	Janus kinase 3	Mus musculus	57-61
35599279-10	2022	In STZ-induced mice, retinal vascular leakage, p-JAK1, p-JAK2, p-JAK3, p-STAT3, and VEGF were significantly increased after diabetes induction.	Streptozocin	3-6	Janus kinase 3	Mus musculus	65-69
35571141-0	2022	Suppression of NLRP3 Inflammasome by Dihydroarteannuin via the HIF-1alpha and JAK3/STAT3 Signaling Pathway Contributes to Attenuation of Collagen-Induced Arthritis in Mice.	dihydroarteannuin	37-54	Janus kinase 3	Mus musculus	78-82
35571141-7	2022	Therefore, we concluded that DHA efficiently alleviated the inflammation and arthritic symptoms in CIA mice and downregulated inflammation in part by inhibiting NLRP3 expression via the HIF-1alpha and JAK3/STAT3 signaling pathway.	dihydroarteannuin	29-32	Janus kinase 3	Mus musculus	201-205
32113685-3	2021	Here, by performing chemical screening for BMP substitutes, we identified a small molecule, TCS21311, that can replace BMP7 and revealed a novel inhibitory role of BMP7 in JAK3-STAT3 signaling in NPC expansion culture.	tcs21311	92-100	Janus kinase 3	Mus musculus	172-176
32639993-8	2020	Importantly, p.T1022I JAK3 mutants displayed higher sensitivity to the JAK3-selective inhibitor Tofacitinib compared to controls.	tofacitinib	96-107	Janus kinase 3	Mus musculus	22-26
33098244-8	2021	AG490 downregulated the phosphorylated activation of JAK3 and their downstream STAT3.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	0-5	Janus kinase 3	Mus musculus	53-57
33214827-0	2020	Hydrogen Peroxide Inducible JAK3 Covalent Inhibitor: Prodrug for the Treatment of RA with Enhanced Safety Profile.	Hydrogen Peroxide	0-17	Janus kinase 3	Mus musculus	28-32
33214827-2	2020	Covalent inhibitors targeting a unique cysteine in JAK3 exhibit ultraselectivity among JAK family members.	Cysteine	39-47	Janus kinase 3	Mus musculus	51-55
33214827-2	2020	Covalent inhibitors targeting a unique cysteine in JAK3 exhibit ultraselectivity among JAK family members.	Cysteine	39-47	Janus kinase 3	Mus musculus	51-54
33214827-4	2020	A prodrug of a known JAK3 covalent inhibitor sensitive to H2O2 was designed and synthesized and its therapeutic effect was evaluated in the CIA (collagen-induced arthritis) mice model of RA (rheumatoid arthritis).	Hydrogen Peroxide	58-62	Janus kinase 3	Mus musculus	21-25
32999332-3	2020	Treatment of mice on a HFD with Quizartinib, a potent inhibitor of FLT3 phosphorylation, inhibits the JAK3/STAT3, signaling and finally antagonizes the accelerated development of AML that occurred following the HFD regimen.	quizartinib	32-43	Janus kinase 3	Mus musculus	102-106
32937124-5	2020	Mechanistically, notopterol directly binds Janus kinase (JAK)2 and JAK3 kinase domains to inhibit JAK/signal transducers and activators of transcription (JAK-STAT) activation, leading to reduced production of inflammatory cytokines and chemokines.	notopterol	17-27	Janus kinase 3	Mus musculus	67-71
32639993-8	2020	Importantly, p.T1022I JAK3 mutants displayed higher sensitivity to the JAK3-selective inhibitor Tofacitinib compared to controls.	tofacitinib	96-107	Janus kinase 3	Mus musculus	71-75
32106727-0	2020	Prevention of DMBA-induced mammary gland tumors in mice by a dual-function inhibitor of JAK3 and EGF receptor tyrosine kinases.	9,10-Dimethyl-1,2-benzanthracene	14-18	Janus kinase 3	Mus musculus	88-92
32097841-4	2020	In this work, poorly selective compounds based on 4- or 6-phenyl-pyrimidine derivatives have been improved to highly potent and selective compounds by designing a covalent binding tether, which attaches to the unique cysteine (Cys909) residue in JAK3.	4- or 6-phenyl-pyrimidine	50-75	Janus kinase 3	Mus musculus	246-250
32097841-4	2020	In this work, poorly selective compounds based on 4- or 6-phenyl-pyrimidine derivatives have been improved to highly potent and selective compounds by designing a covalent binding tether, which attaches to the unique cysteine (Cys909) residue in JAK3.	Cysteine	217-225	Janus kinase 3	Mus musculus	246-250
31866272-4	2020	Among them, the most potent JAK3 inhibitor, namely 8e (IC50 = 1.38 nM), significantly reduced the degree of airsacculitis and fibrosis according to hematoxylin-eosin (HE) staining assay for the lung tissue in the bleomycin (BLM)-induced pulmonary fibrosis mouse model.	Bleomycin	213-222	Janus kinase 3	Mus musculus	28-32
32038231-0	2019	The Anticancer Effects of Atractylenolide III Associate With the Downregulation of Jak3/Stat3-Dependent IDO Expression.	atractylenolide III	26-45	Janus kinase 3	Mus musculus	83-87
32038231-3	2019	This study is to determine the anticancer effects of ATLIII with the Jak3/Stat3-dependent IDO inactivation.	atractylenolide III	53-59	Janus kinase 3	Mus musculus	69-73
32038231-6	2019	We also determined the efficacy of ATLIII on Jak3/Stat3 pathway expression induced by IFN-gamma and Jak3/Stat3-dependent IDO activation.	atractylenolide III	35-41	Janus kinase 3	Mus musculus	45-49
32038231-7	2019	Further molecular docking assay predicted the binding activity and site of ATLIII to Jak3 protein.	atractylenolide III	75-81	Janus kinase 3	Mus musculus	85-89
32038231-11	2019	ATLIII reduced the phosphorylation level of Jak3 and Stat3 in response to IFN-gamma stimulation, then remarkably reduced the nuclear translocation of p-Stat3 by IFN-gamma.	atractylenolide III	0-6	Janus kinase 3	Mus musculus	44-48
31866272-0	2020	Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.	thieno[3,2-d]pyrimidines	37-61	Janus kinase 3	Mus musculus	72-76
31866272-3	2020	In this study, through the use of a conformationally-constrained design strategy, a series of thieno[3,2-d]pyrimidines were synthesized as potent JAK3 inhibitors for the treatment of IPF.	thieno[3,2-d]pyrimidines	94-118	Janus kinase 3	Mus musculus	146-150
31866272-4	2020	Among them, the most potent JAK3 inhibitor, namely 8e (IC50 = 1.38 nM), significantly reduced the degree of airsacculitis and fibrosis according to hematoxylin-eosin (HE) staining assay for the lung tissue in the bleomycin (BLM)-induced pulmonary fibrosis mouse model.	Hematoxylin Eosin	148-165	Janus kinase 3	Mus musculus	28-32
31866272-4	2020	Among them, the most potent JAK3 inhibitor, namely 8e (IC50 = 1.38 nM), significantly reduced the degree of airsacculitis and fibrosis according to hematoxylin-eosin (HE) staining assay for the lung tissue in the bleomycin (BLM)-induced pulmonary fibrosis mouse model.	Helium	167-169	Janus kinase 3	Mus musculus	28-32
32038231-13	2019	Molecular docking assay showed that the oxygen atom on the five-membered ring of ATLIII was capable of forming a hydrogen bond with Leu905-NH2 site of Jak3 protein.	Oxygen	40-46	Janus kinase 3	Mus musculus	151-155
32038231-13	2019	Molecular docking assay showed that the oxygen atom on the five-membered ring of ATLIII was capable of forming a hydrogen bond with Leu905-NH2 site of Jak3 protein.	atractylenolide III	81-87	Janus kinase 3	Mus musculus	151-155
32038231-13	2019	Molecular docking assay showed that the oxygen atom on the five-membered ring of ATLIII was capable of forming a hydrogen bond with Leu905-NH2 site of Jak3 protein.	Hydrogen	113-121	Janus kinase 3	Mus musculus	151-155
32038231-13	2019	Molecular docking assay showed that the oxygen atom on the five-membered ring of ATLIII was capable of forming a hydrogen bond with Leu905-NH2 site of Jak3 protein.	pinazepam	132-142	Janus kinase 3	Mus musculus	151-155
32038231-16	2019	Conclusion: ATLIII has shown significant efficacy to inhibit IFN-gamma-triggered Jak3/Stat3 pathway-dependent IDO activation, and do so through a direct binding to Jak3 protein.	atractylenolide III	12-18	Janus kinase 3	Mus musculus	81-85
32038231-16	2019	Conclusion: ATLIII has shown significant efficacy to inhibit IFN-gamma-triggered Jak3/Stat3 pathway-dependent IDO activation, and do so through a direct binding to Jak3 protein.	atractylenolide III	12-18	Janus kinase 3	Mus musculus	164-168
31866272-4	2020	Among them, the most potent JAK3 inhibitor, namely 8e (IC50 = 1.38 nM), significantly reduced the degree of airsacculitis and fibrosis according to hematoxylin-eosin (HE) staining assay for the lung tissue in the bleomycin (BLM)-induced pulmonary fibrosis mouse model.	Bleomycin	224-227	Janus kinase 3	Mus musculus	28-32
29959623-5	2018	More, AS significantly reduced the protein expression of JAK3/STAT3/NF-kappaB pathway in CS-induced mice.	Cesium	89-91	Janus kinase 3	Mus musculus	57-61
31078568-8	2019	SRI110 co-treatment reversed the cisplatin-induced changes in the expression levels of Bcl2l1, Ccnd1, Jak2, Jak3, and Src and significantly attenuated the changes in the expression levels of Cdkn1a, Egfr, Fas, Il6st, Jak1, Stat3, and Tyk2.	sri110	0-6	Janus kinase 3	Mus musculus	108-112
31078568-8	2019	SRI110 co-treatment reversed the cisplatin-induced changes in the expression levels of Bcl2l1, Ccnd1, Jak2, Jak3, and Src and significantly attenuated the changes in the expression levels of Cdkn1a, Egfr, Fas, Il6st, Jak1, Stat3, and Tyk2.	Cisplatin	33-42	Janus kinase 3	Mus musculus	108-112
30129110-13	2018	ESA inhibited the level of JAK3, phosphorylation of Stat5 and Stat3, and Foxp3 in EL4 cells.	esa	0-3	Janus kinase 3	Mus musculus	27-31
30129110-17	2018	ESA suppressed the level of Foxp3 via inhibiting IL-2Rgamma/JAK3/Stats signaling pathway in EL4 cells.	esa	0-3	Janus kinase 3	Mus musculus	60-64
30993508-1	2019	Preformulation studies on tofacitinib citrate, a small molecule JAK3 specific inhibitor, have not been previously reported in literature.	tofacitinib	26-45	Janus kinase 3	Mus musculus	64-68
30064075-12	2018	CONCLUSION: Indirubin alleviates IMQ-induced psoriasis-like dermatitis mainly through reducing the inflammatory responses mediated by IL-17 A-producing gammadelta T cells involving Jak3/Stat3 activation.	Imiquimod	33-36	Janus kinase 3	Mus musculus	181-185
28539220-2	2017	Substitution at the C6 position of the pyrrolopyridazine core with aryl groups provided exceptional biochemical potency against JAK1 and JAK3 while maintaining good selectivity against JAK2 and Tyk2.	Pyrrolopyridazine	39-56	Janus kinase 3	Mus musculus	137-141
29986854-7	2018	Finally, we assessed the efficacy of JAK3 inhibition and showed that CTCL JAK3A572V-positive T cells are sensitive to tofacitinib, which provides additional preclinical insights into the use of JAK3 inhibitors in these disorders.	tofacitinib	118-129	Janus kinase 3	Mus musculus	37-41
28893602-0	2018	Raltegravir blocks the infectivity of red-fluorescent-protein (mCherry)-labeled HIV-1JR-FL in the setting of post-exposure prophylaxis in NOD/SCID/Jak3-/- mice transplanted with human PBMCs.	Raltegravir Potassium	0-11	Janus kinase 3	Mus musculus	147-151
28884378-1	2017	Tofacitinib is a Janus kinase 3 (JAK3) inhibitor that promotes hair growth; however, the efficacy and mechanism of this effect are not yet understood.	tofacitinib	0-11	Janus kinase 3	Mus musculus	17-31
28884378-1	2017	Tofacitinib is a Janus kinase 3 (JAK3) inhibitor that promotes hair growth; however, the efficacy and mechanism of this effect are not yet understood.	tofacitinib	0-11	Janus kinase 3	Mus musculus	33-37
28332288-4	2017	Tetrandrine inhibited the phosphorylation of signal transducer and activator of transcription-3 (STAT3) and boosted the phosphorylation of STAT5, while it did not alter the expression levels of phospho-Janus kinase-1 (p-JAK1), p-JAK2, p-JAK3, and suppressor of cytokine signalling-3 (SOCS3).	tetrandrine	0-11	Janus kinase 3	Mus musculus	237-241
28790974-5	2017	However, inhibition of JAK3 confirmed by reduced phosphorylation of its activation loop at tyrosine residues 980/981 does not reduce infarct volume measured at 48 h after stroke (n = 6-10/group) nor does it alter behavioral outcomes sensitive to neurological deficits or stroke-induced neuroinflammatory response (n = 9-10/group).	Tyrosine	91-99	Janus kinase 3	Mus musculus	23-27
29986854-7	2018	Finally, we assessed the efficacy of JAK3 inhibition and showed that CTCL JAK3A572V-positive T cells are sensitive to tofacitinib, which provides additional preclinical insights into the use of JAK3 inhibitors in these disorders.	tofacitinib	118-129	Janus kinase 3	Mus musculus	74-78
29411195-1	2018	Here, we report the design and synthesis of pyrimidinyl heterocyclic compounds containing terminal electrophiles as irreversible covalent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3.	Cysteine	176-184	Janus kinase 3	Mus musculus	138-142
29411195-1	2018	Here, we report the design and synthesis of pyrimidinyl heterocyclic compounds containing terminal electrophiles as irreversible covalent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3.	Cysteine	176-184	Janus kinase 3	Mus musculus	205-209
29411195-3	2018	Among them, T29 was verified as a promising JAK3 irreversible inhibitor that possessed the best bioactivity and selectivity against JAKs and kinases containing a cysteine in the residue analogous to Cys909 in JAK3, suggesting that covalent modification of this Cys residue allowed the identification of a highly selective JAK3 inhibitor.	Cysteine	162-170	Janus kinase 3	Mus musculus	44-48
29411195-3	2018	Among them, T29 was verified as a promising JAK3 irreversible inhibitor that possessed the best bioactivity and selectivity against JAKs and kinases containing a cysteine in the residue analogous to Cys909 in JAK3, suggesting that covalent modification of this Cys residue allowed the identification of a highly selective JAK3 inhibitor.	Cysteine	199-202	Janus kinase 3	Mus musculus	44-48
29411195-3	2018	Among them, T29 was verified as a promising JAK3 irreversible inhibitor that possessed the best bioactivity and selectivity against JAKs and kinases containing a cysteine in the residue analogous to Cys909 in JAK3, suggesting that covalent modification of this Cys residue allowed the identification of a highly selective JAK3 inhibitor.	Cysteine	199-202	Janus kinase 3	Mus musculus	209-213
29411195-3	2018	Among them, T29 was verified as a promising JAK3 irreversible inhibitor that possessed the best bioactivity and selectivity against JAKs and kinases containing a cysteine in the residue analogous to Cys909 in JAK3, suggesting that covalent modification of this Cys residue allowed the identification of a highly selective JAK3 inhibitor.	Cysteine	199-202	Janus kinase 3	Mus musculus	209-213
29588471-3	2018	In this article, we developed the 4-aminopiperidine-based compound RB1, which was highly selective for JAK3 inhibition, with an IC50 of value of 40 nM, but did not inhibit JAK1, JAK2 or tyrosine kinase 2 (TYK2) at concentrations up to 5 microM.	4-aminopiperidine	34-51	Janus kinase 3	Mus musculus	103-107
29588471-6	2018	A combination of liquid chromatography-mass spectrometry (LC-MS) experiments validated that RB1 covalently modified the unique cysteine 909 residue in JAK3.	Cysteine	127-135	Janus kinase 3	Mus musculus	151-155
28852199-4	2018	Signaling pathways regulated by JAK3 mutants were assessed following acute inhibition of JAK1/JAK3 using the JAK kinase inhibitors ruxolitinib or tofacitinib.	ruxolitinib	131-142	Janus kinase 3	Mus musculus	32-36
28852199-4	2018	Signaling pathways regulated by JAK3 mutants were assessed following acute inhibition of JAK1/JAK3 using the JAK kinase inhibitors ruxolitinib or tofacitinib.	tofacitinib	146-157	Janus kinase 3	Mus musculus	32-36
28944566-2	2017	Based on the unique cysteine 909 residue (Cys909) of JAK3 at the gatekeeper position, we have developed a new irreversible covalent inhibitor, III-4, which is highly potent and selective in targeting JAK3.	Cysteine	20-28	Janus kinase 3	Mus musculus	53-57
28944566-2	2017	Based on the unique cysteine 909 residue (Cys909) of JAK3 at the gatekeeper position, we have developed a new irreversible covalent inhibitor, III-4, which is highly potent and selective in targeting JAK3.	Cysteine	20-28	Janus kinase 3	Mus musculus	200-204
28251448-0	2017	Effects of Ergosterol on COPD in Mice via JAK3/STAT3/NF-kappaB Pathway.	Ergosterol	11-21	Janus kinase 3	Mus musculus	42-46
28251448-6	2017	Furthermore, ER significantly inhibited the protein expression of JAK3/STAT3/NF-kappaB pathway in CS-induced mice.	Cesium	98-100	Janus kinase 3	Mus musculus	66-70
27745702-3	2017	In mice with diphtheria toxin receptor expression in proximal tubules (selective injury model), a relatively selective JAK3 inhibitor, tofacitinib, led to more severe kidney injury, delayed recovery from acute kidney injury, increased inflammatory M1 phenotype markers and decreased reparative M2 phenotype markers of macrophages/dendritic cells, and development of more severe renal fibrosis after diphtheria toxin administration.	tofacitinib	135-146	Janus kinase 3	Mus musculus	119-123
28284718-5	2017	Proliferation of Ba/F3 cells transduced with novel JAK3 mutations (JAK3H583Y and JAK3G589D) was independent of IL-3 and was inhibited by the JAK3 inhibitor tofacitinib (means +- SD drug concentration causing a 50% inhibition of the desired activity, 85 +- 10 nmol/L and 54 +- 9 nmol/L).	tofacitinib	156-167	Janus kinase 3	Mus musculus	51-55
28284718-5	2017	Proliferation of Ba/F3 cells transduced with novel JAK3 mutations (JAK3H583Y and JAK3G589D) was independent of IL-3 and was inhibited by the JAK3 inhibitor tofacitinib (means +- SD drug concentration causing a 50% inhibition of the desired activity, 85 +- 10 nmol/L and 54 +- 9 nmol/L).	tofacitinib	156-167	Janus kinase 3	Mus musculus	67-71
28272448-7	2017	Furthermore, histamine enhanced the signal transducer and activator of transcription (STAT)-6 phosphorylation level in murine heart fibroblasts, and the inhibitive effects of histamine on fibroblast proliferation could be blocked by JAK3/STAT6 signaling selective antagonist.	Histamine	13-22	Janus kinase 3	Mus musculus	233-237
28272448-7	2017	Furthermore, histamine enhanced the signal transducer and activator of transcription (STAT)-6 phosphorylation level in murine heart fibroblasts, and the inhibitive effects of histamine on fibroblast proliferation could be blocked by JAK3/STAT6 signaling selective antagonist.	Histamine	175-184	Janus kinase 3	Mus musculus	233-237
28066259-0	2016	IL-15 Activates the Jak3/STAT3 Signaling Pathway to Mediate Glucose Uptake in Skeletal Muscle Cells.	Glucose	60-67	Janus kinase 3	Mus musculus	20-24
28274306-8	2017	GA inhibited the protein levels of GATA3, p-JAK3, p-STAT3, p-NF-kappaB, p-IkappaBalpha and increased T-bet protein in MRL/lpr mice.	Glycyrrhizic Acid	0-2	Janus kinase 3	Mus musculus	44-48
27487096-14	2016	Amitriptyline, a commonly used antidepressant that blocks the acid sphingomyelinase, or acid sphingomyelinase-deficiency reduced stress-induced phosphorylation of Jak-3.	Amitriptyline	0-13	Janus kinase 3	Mus musculus	163-168
27732937-4	2016	We then evaluated the antitumor effects of the selective JAK3 inhibitor, tofacitinib, against these cell lines in vitro and in a murine xenograft model.	tofacitinib	73-84	Janus kinase 3	Mus musculus	57-61
26784569-0	2016	Astilbin inhibits Th17 cell differentiation and ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via Jak3/Stat3 signaling pathway.	astilbin	0-8	Janus kinase 3	Mus musculus	125-129
29046866-10	2016	CONCLUSION: Jak3 inhibitors CP-690,550 and NC1153 showed efficacy in reducing viability of Ba/F3 cells transformed with mutant forms of Jak3, thus providing new therapeutic strategies to treat these types of cancer.	tofacitinib	28-34	Janus kinase 3	Mus musculus	12-16
27278657-13	2016	CONCLUSIONS: On the basis of our results, we conclude that the JAK-STAT pathway is implicated in the progression of renal inflammation in NZB/WF1 mice and that targeting JAK3 with CP-690,550 is effective in slowing down the course of experimental LN.	tofacitinib	180-186	Janus kinase 3	Mus musculus	170-174
26451047-7	2015	Mechanistically, Jak3 was essential for reduced expression and activation of Toll-like receptors (TLRs) in murine intestinal mucosa and human intestinal epithelial cells where Jak3 interacted with and activated p85, the regulatory subunit of the PI3K, through tyrosine phosphorylation of adapter protein insulin receptor substrate (IRS1).	Tyrosine	260-268	Janus kinase 3	Mus musculus	17-21
26623026-5	2015	FAE and QR significantly potentiated pentobarbital-induced [50 mg/kg, intraperitoneal (ip)] sleep (prolonged sleeping time; shortened sleep latency) in a dose-dependent manner, and these effects were augmented by administration of 5-hydroxytryptophan (5-HTP), a precursor of 5-hydroxytryptamine.	Pentobarbital	37-50	Janus kinase 3	Mus musculus	0-3
29046866-10	2016	CONCLUSION: Jak3 inhibitors CP-690,550 and NC1153 showed efficacy in reducing viability of Ba/F3 cells transformed with mutant forms of Jak3, thus providing new therapeutic strategies to treat these types of cancer.	tofacitinib	28-34	Janus kinase 3	Mus musculus	136-140
26446793-6	2015	The same cytokine receptor independence as for JAK3(L857P) was observed for homologous Leu(857) mutations of JAK1 and JAK2 and for JAK3(L875H).	Leucine	87-90	Janus kinase 3	Mus musculus	47-51
26446793-10	2015	Moreover, ruxolitinib, which preferentially blocks JAK1 and JAK2, abolished the proliferation of cells transformed by the receptor-dependent JAK3(V674A), yet proved much less potent on cells expressing JAK3(L857P).	ruxolitinib	10-21	Janus kinase 3	Mus musculus	141-145
26446793-10	2015	Moreover, ruxolitinib, which preferentially blocks JAK1 and JAK2, abolished the proliferation of cells transformed by the receptor-dependent JAK3(V674A), yet proved much less potent on cells expressing JAK3(L857P).	ruxolitinib	10-21	Janus kinase 3	Mus musculus	202-206
26623026-5	2015	FAE and QR significantly potentiated pentobarbital-induced [50 mg/kg, intraperitoneal (ip)] sleep (prolonged sleeping time; shortened sleep latency) in a dose-dependent manner, and these effects were augmented by administration of 5-hydroxytryptophan (5-HTP), a precursor of 5-hydroxytryptamine.	5-Hydroxytryptophan	231-250	Janus kinase 3	Mus musculus	0-3
26623026-5	2015	FAE and QR significantly potentiated pentobarbital-induced [50 mg/kg, intraperitoneal (ip)] sleep (prolonged sleeping time; shortened sleep latency) in a dose-dependent manner, and these effects were augmented by administration of 5-hydroxytryptophan (5-HTP), a precursor of 5-hydroxytryptamine.	5-Hydroxytryptophan	252-257	Janus kinase 3	Mus musculus	0-3
26623026-5	2015	FAE and QR significantly potentiated pentobarbital-induced [50 mg/kg, intraperitoneal (ip)] sleep (prolonged sleeping time; shortened sleep latency) in a dose-dependent manner, and these effects were augmented by administration of 5-hydroxytryptophan (5-HTP), a precursor of 5-hydroxytryptamine.	Serotonin	275-294	Janus kinase 3	Mus musculus	0-3
26623026-6	2015	With a sub-hypnotic dose of pentobarbital (28 mg/kg, ip), FAE and QR significantly increased the rate of sleep onset and were synergistic with 5-HTP (2.5 mg/kg, ip).	Pentobarbital	28-41	Janus kinase 3	Mus musculus	58-61
26623026-7	2015	Pretreatment with p-chlorophenylalanine, an inhibitor of tryptophan hydroxylase, significantly decreased sleeping time and prolonged sleep latency in pentobarbital-treated mice, whereas FAE and QR significantly reversed this effect.	Pentobarbital	150-163	Janus kinase 3	Mus musculus	186-189
25493954-0	2015	Janus kinase 3 regulates renal 25-hydroxyvitamin D 1alpha-hydroxylase expression, calcitriol formation, and phosphate metabolism.	Calcitriol	82-92	Janus kinase 3	Mus musculus	0-14
26164790-2	2015	We focused on the 2 different JAK inhibitors, tofacitinib (selective for JAK3) and oclacitinib (selective for JAK1 and 2), to clarify the mechanism of anti-inflammatory and anti-itching potency of these drugs.	tofacitinib	46-57	Janus kinase 3	Mus musculus	73-77
25655587-4	2015	Western blot analysis showed that piperine blocked the IL-2-induced phosphorylation of signal transducer and activator of transcription (STAT) 3 and STAT5 without affecting the upstream phosphorylation of Janus kinase (JAK) 1 and JAK3.	piperine	34-42	Janus kinase 3	Mus musculus	230-234
25826541-5	2015	Mice lacking JAK3, a kinase essential for immune homeostasis, displayed mild renal inflammation, elevated renal CYP27B1 expression, and altered phosphate metabolism, linking immune signaling to vitamin D metabolism in the kidney.	Phosphates	144-153	Janus kinase 3	Mus musculus	13-17
25826541-5	2015	Mice lacking JAK3, a kinase essential for immune homeostasis, displayed mild renal inflammation, elevated renal CYP27B1 expression, and altered phosphate metabolism, linking immune signaling to vitamin D metabolism in the kidney.	Vitamin D	194-203	Janus kinase 3	Mus musculus	13-17
25493954-0	2015	Janus kinase 3 regulates renal 25-hydroxyvitamin D 1alpha-hydroxylase expression, calcitriol formation, and phosphate metabolism.	Phosphates	108-117	Janus kinase 3	Mus musculus	0-14
25493954-8	2015	Thus, JAK3 is a powerful regulator of 1alpha-hydroxylase expression and phosphate transport.	Phosphates	72-81	Janus kinase 3	Mus musculus	6-10
26279433-8	2015	Addition of ATP (100 microM) was followed by transient increase of [Ca(2+)]i reflecting Ca(2+) release from intracellular stores, an effect significantly less pronounced in jak3(-/-) DCs than in jak3(+/+) DCs.	Adenosine Triphosphate	12-15	Janus kinase 3	Mus musculus	173-177
26021261-7	2015	Energy depletion by 4h pre-treatment with 2,4-dinitro-phenol significantly decreased Ipump in jak3(+/+) DCs but not in jak3(-/-)DCs.	4h	20-22	Janus kinase 3	Mus musculus	94-98
26021261-7	2015	Energy depletion by 4h pre-treatment with 2,4-dinitro-phenol significantly decreased Ipump in jak3(+/+) DCs but not in jak3(-/-)DCs.	2,4-Dinitrophenol	42-60	Janus kinase 3	Mus musculus	94-98
26021261-7	2015	Energy depletion by 4h pre-treatment with 2,4-dinitro-phenol significantly decreased Ipump in jak3(+/+) DCs but not in jak3(-/-)DCs.	ipump	85-90	Janus kinase 3	Mus musculus	94-98
26021261-8	2015	Cellular ATP was significantly lower in jak3(-/-)DCs than in jak3(+/+)DCs and decreased in both genotypes by 2,4-dinitro-phenol, an effect significantly more pronounced in jak3(-/-)DCs than in jak3(+/+)DCs and strongly blunted by ouabain in both jak3(+/+) and jak3(-/-)DCs.	Adenosine Triphosphate	9-12	Janus kinase 3	Mus musculus	40-44
26021261-8	2015	Cellular ATP was significantly lower in jak3(-/-)DCs than in jak3(+/+)DCs and decreased in both genotypes by 2,4-dinitro-phenol, an effect significantly more pronounced in jak3(-/-)DCs than in jak3(+/+)DCs and strongly blunted by ouabain in both jak3(+/+) and jak3(-/-)DCs.	Adenosine Triphosphate	9-12	Janus kinase 3	Mus musculus	61-65
26021261-8	2015	Cellular ATP was significantly lower in jak3(-/-)DCs than in jak3(+/+)DCs and decreased in both genotypes by 2,4-dinitro-phenol, an effect significantly more pronounced in jak3(-/-)DCs than in jak3(+/+)DCs and strongly blunted by ouabain in both jak3(+/+) and jak3(-/-)DCs.	Adenosine Triphosphate	9-12	Janus kinase 3	Mus musculus	61-65
25587856-5	2015	We demonstrate that H5N1 HA attachment inhibits cAMP-dependent CFTR Cl(-) channels via JAK3-mediated adenylyl cyclase (AC) suppression, which reduces cAMP production.	Cyclic AMP	48-52	Janus kinase 3	Mus musculus	87-91
25587856-5	2015	We demonstrate that H5N1 HA attachment inhibits cAMP-dependent CFTR Cl(-) channels via JAK3-mediated adenylyl cyclase (AC) suppression, which reduces cAMP production.	Cyclic AMP	150-154	Janus kinase 3	Mus musculus	87-91
25587856-9	2015	Our findings provide novel insight into the pathogenesis of acute lung injury via the inhibition of cAMP-dependent CFTR channels, indicating that the administration of cAMP-elevating agents and targeting JAK3 may activate host tolerance to infection for the management of influenza virus-induced fatal pneumonia.	Cyclic AMP	100-104	Janus kinase 3	Mus musculus	204-208
26021261-8	2015	Cellular ATP was significantly lower in jak3(-/-)DCs than in jak3(+/+)DCs and decreased in both genotypes by 2,4-dinitro-phenol, an effect significantly more pronounced in jak3(-/-)DCs than in jak3(+/+)DCs and strongly blunted by ouabain in both jak3(+/+) and jak3(-/-)DCs.	Adenosine Triphosphate	9-12	Janus kinase 3	Mus musculus	61-65
26279433-8	2015	Addition of ATP (100 microM) was followed by transient increase of [Ca(2+)]i reflecting Ca(2+) release from intracellular stores, an effect significantly less pronounced in jak3(-/-) DCs than in jak3(+/+) DCs.	Adenosine Triphosphate	12-15	Janus kinase 3	Mus musculus	195-199
26021261-8	2015	Cellular ATP was significantly lower in jak3(-/-)DCs than in jak3(+/+)DCs and decreased in both genotypes by 2,4-dinitro-phenol, an effect significantly more pronounced in jak3(-/-)DCs than in jak3(+/+)DCs and strongly blunted by ouabain in both jak3(+/+) and jak3(-/-)DCs.	Adenosine Triphosphate	9-12	Janus kinase 3	Mus musculus	61-65
26021261-8	2015	Cellular ATP was significantly lower in jak3(-/-)DCs than in jak3(+/+)DCs and decreased in both genotypes by 2,4-dinitro-phenol, an effect significantly more pronounced in jak3(-/-)DCs than in jak3(+/+)DCs and strongly blunted by ouabain in both jak3(+/+) and jak3(-/-)DCs.	Adenosine Triphosphate	9-12	Janus kinase 3	Mus musculus	61-65
26279433-10	2015	In addition, the Ca(2+) release-activated Ca(2+) channel (CRAC) current triggered by IP3-induced Ca(2+) store depletion and CXCL12 was significantly higher in DCs from jak3(+/+) mice than in jak3(-/-) mice.	Inositol 1,4,5-Trisphosphate	85-88	Janus kinase 3	Mus musculus	168-172
26021261-9	2015	Ipump and Iouabain in oocytes were decreased by expression of JAK3 and of (A568V)JAK3 but not of (K851A)JAK3.	ipump	0-5	Janus kinase 3	Mus musculus	62-66
26021261-9	2015	Ipump and Iouabain in oocytes were decreased by expression of JAK3 and of (A568V)JAK3 but not of (K851A)JAK3.	ipump	0-5	Janus kinase 3	Mus musculus	81-85
26021261-9	2015	Ipump and Iouabain in oocytes were decreased by expression of JAK3 and of (A568V)JAK3 but not of (K851A)JAK3.	ipump	0-5	Janus kinase 3	Mus musculus	81-85
26279433-10	2015	In addition, the Ca(2+) release-activated Ca(2+) channel (CRAC) current triggered by IP3-induced Ca(2+) store depletion and CXCL12 was significantly higher in DCs from jak3(+/+) mice than in jak3(-/-) mice.	Inositol 1,4,5-Trisphosphate	85-88	Janus kinase 3	Mus musculus	191-195
26021261-9	2015	Ipump and Iouabain in oocytes were decreased by expression of JAK3 and of (A568V)JAK3 but not of (K851A)JAK3.	iouabain	10-18	Janus kinase 3	Mus musculus	62-66
26021261-9	2015	Ipump and Iouabain in oocytes were decreased by expression of JAK3 and of (A568V)JAK3 but not of (K851A)JAK3.	iouabain	10-18	Janus kinase 3	Mus musculus	81-85
26279433-13	2015	Pretreatment of jak3(+/+) DCs with JAK inhibitor WHI-P154 (22 microM, 10 minutes or 24 hours) significantly blunted both thapsigargin induced Ca(2+) release and subsequent SOCE.	WHI P154	49-57	Janus kinase 3	Mus musculus	16-20
26021261-9	2015	Ipump and Iouabain in oocytes were decreased by expression of JAK3 and of (A568V)JAK3 but not of (K851A)JAK3.	iouabain	10-18	Janus kinase 3	Mus musculus	81-85
26021261-10	2015	JAK3 inhibitor WHI-P154 (4-[(3"-bromo-4"-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 22 muM) enhanced Ipump and Iouabain in JAK3 expressing oocytes.	WHI P154	15-23	Janus kinase 3	Mus musculus	0-4
26279433-13	2015	Pretreatment of jak3(+/+) DCs with JAK inhibitor WHI-P154 (22 microM, 10 minutes or 24 hours) significantly blunted both thapsigargin induced Ca(2+) release and subsequent SOCE.	Thapsigargin	121-133	Janus kinase 3	Mus musculus	16-20
26021261-10	2015	JAK3 inhibitor WHI-P154 (4-[(3"-bromo-4"-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 22 muM) enhanced Ipump and Iouabain in JAK3 expressing oocytes.	WHI P154	15-23	Janus kinase 3	Mus musculus	127-131
26021261-10	2015	JAK3 inhibitor WHI-P154 (4-[(3"-bromo-4"-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 22 muM) enhanced Ipump and Iouabain in JAK3 expressing oocytes.	WHI P154	25-86	Janus kinase 3	Mus musculus	0-4
26021261-10	2015	JAK3 inhibitor WHI-P154 (4-[(3"-bromo-4"-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 22 muM) enhanced Ipump and Iouabain in JAK3 expressing oocytes.	WHI P154	25-86	Janus kinase 3	Mus musculus	127-131
26021261-10	2015	JAK3 inhibitor WHI-P154 (4-[(3"-bromo-4"-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 22 muM) enhanced Ipump and Iouabain in JAK3 expressing oocytes.	ipump	105-110	Janus kinase 3	Mus musculus	0-4
26021261-10	2015	JAK3 inhibitor WHI-P154 (4-[(3"-bromo-4"-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 22 muM) enhanced Ipump and Iouabain in JAK3 expressing oocytes.	ipump	105-110	Janus kinase 3	Mus musculus	127-131
26021261-10	2015	JAK3 inhibitor WHI-P154 (4-[(3"-bromo-4"-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline, 22 muM) enhanced Ipump and Iouabain in JAK3 expressing oocytes.	iouabain	115-123	Janus kinase 3	Mus musculus	0-4
26303250-9	2015	The decline of conductance in BK and JAK3 coexpressing oocytes following inhibition of channel protein insertion by brefeldin A (5 microM) was similar in oocytes expressing BK with JAK3 and oocytes expressing BK alone, indicating that JAK3 might slow channel protein insertion into rather than accelerating channel protein retrieval from the cell membrane.	Brefeldin A	116-127	Janus kinase 3	Mus musculus	37-41
26021261-11	2015	The difference between (A568V)JAK3 and (K851A)JAK3 expressing oocytes was virtually abrogated by actinomycin D (50 nM).	Dactinomycin	97-110	Janus kinase 3	Mus musculus	30-34
26021261-11	2015	The difference between (A568V)JAK3 and (K851A)JAK3 expressing oocytes was virtually abrogated by actinomycin D (50 nM).	Dactinomycin	97-110	Janus kinase 3	Mus musculus	46-50
26021261-12	2015	CONCLUSIONS: JAK3 down-regulates Na(+)/K(+)-ATPase activity, an effect involving gene expression and profoundly curtailing ATP consumption.	Adenosine Triphosphate	44-47	Janus kinase 3	Mus musculus	13-17
24928228-5	2014	This study thus explored whether JAK3 regulates glutamate transporters EAAT1-4, carriers accomplishing transport of glutamate and aspartate in a variety of cells including intestinal cells, renal cells, glial cells, and neurons.	Aspartic Acid	130-139	Janus kinase 3	Mus musculus	33-37
24992071-9	2014	DX8-treated cancer cells showed clear degradation of kinase JAK3/STAT3 protein levels.	CHEMBL577934	0-3	Janus kinase 3	Mus musculus	60-64
24992071-11	2014	Collectively, our results demonstrate potent anti-angiogenic, and selective JAK3/STAT3 down-regulating anticancer characteristics of DX8, a new dexamethasone-based antitumor molecule.	Dexamethasone	144-157	Janus kinase 3	Mus musculus	76-80
24928228-3	2014	Replacement of ATP coordinating lysine by alanine yields inactive JAK3(K855A).	Adenosine Triphosphate	15-18	Janus kinase 3	Mus musculus	66-70
24928228-3	2014	Replacement of ATP coordinating lysine by alanine yields inactive JAK3(K855A).	Lysine	32-38	Janus kinase 3	Mus musculus	66-70
24928228-3	2014	Replacement of ATP coordinating lysine by alanine yields inactive JAK3(K855A).	Alanine	42-49	Janus kinase 3	Mus musculus	66-70
24928228-5	2014	This study thus explored whether JAK3 regulates glutamate transporters EAAT1-4, carriers accomplishing transport of glutamate and aspartate in a variety of cells including intestinal cells, renal cells, glial cells, and neurons.	Glutamic Acid	48-57	Janus kinase 3	Mus musculus	33-37
25193870-7	2014	In vivo treatment of leukemic mice with the JAK3 selective inhibitor tofacitinib reduced the white blood cell count and caused leukemic cell apoptosis.	tofacitinib	69-80	Janus kinase 3	Mus musculus	44-48
24928228-8	2014	As a result, in EAAT1, 2, 3, or 4 expressing oocytes, but not in oocytes injected with water, addition of glutamate to extracellular bath generated an inward current (Ig), which was significantly increased following coexpression of JAK3.	Glutamic Acid	106-115	Janus kinase 3	Mus musculus	232-236
24928228-10	2014	Ig in EAAT3 + JAK3 expressing oocytes was significantly decreased by JAK3 inhibitor WHI-P154 (22 microM).	WHI P154	84-92	Janus kinase 3	Mus musculus	14-18
24928228-10	2014	Ig in EAAT3 + JAK3 expressing oocytes was significantly decreased by JAK3 inhibitor WHI-P154 (22 microM).	WHI P154	84-92	Janus kinase 3	Mus musculus	69-73
24928228-11	2014	Kinetic analysis revealed that JAK3 increased maximal Ig and significantly reduced the glutamate concentration required for half maximal Ig (Km).	Glutamic Acid	87-96	Janus kinase 3	Mus musculus	31-35
24928228-12	2014	Intestinal electrogenic glutamate transport was significantly lower in jak3(-/-) than in jak3(+/+) mice.	Glutamic Acid	24-33	Janus kinase 3	Mus musculus	71-75
24928228-12	2014	Intestinal electrogenic glutamate transport was significantly lower in jak3(-/-) than in jak3(+/+) mice.	Glutamic Acid	24-33	Janus kinase 3	Mus musculus	89-93
23934551-2	2013	Replacement of lysine by alanine in the catalytic subunit yields the inactive (K851A)JAK3 mutant that underlies severe combined immune deficiency.	Lysine	15-21	Janus kinase 3	Mus musculus	85-89
23689514-6	2014	In a human NKCL xenograft mouse model, tumor growth was significantly delayed by the JAK3 inhibitor CP-690550.	tofacitinib	100-109	Janus kinase 3	Mus musculus	85-89
23934551-2	2013	Replacement of lysine by alanine in the catalytic subunit yields the inactive (K851A)JAK3 mutant that underlies severe combined immune deficiency.	Alanine	25-32	Janus kinase 3	Mus musculus	85-89
23934551-11	2013	In PEPT1- and PEPT2-expressing oocytes, but not in water-injected oocytes, the dipeptide gly-gly generated an inward current, which was significantly increased following coexpression of JAK3.	Dipeptides	79-88	Janus kinase 3	Mus musculus	186-190
23934551-11	2013	In PEPT1- and PEPT2-expressing oocytes, but not in water-injected oocytes, the dipeptide gly-gly generated an inward current, which was significantly increased following coexpression of JAK3.	Glycylglycine	89-96	Janus kinase 3	Mus musculus	186-190
23934551-15	2013	In JAK3- and PEPT1-expressing oocytes, peptide-induced current was blunted by the JAK3 inhibitor WHI-P154, 4-[(3"-bromo-4"-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline (22 muM).	WHI P154	97-105	Janus kinase 3	Mus musculus	3-7
23934551-15	2013	In JAK3- and PEPT1-expressing oocytes, peptide-induced current was blunted by the JAK3 inhibitor WHI-P154, 4-[(3"-bromo-4"-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline (22 muM).	WHI P154	97-105	Janus kinase 3	Mus musculus	82-86
23934551-15	2013	In JAK3- and PEPT1-expressing oocytes, peptide-induced current was blunted by the JAK3 inhibitor WHI-P154, 4-[(3"-bromo-4"-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline (22 muM).	WHI P154	107-168	Janus kinase 3	Mus musculus	3-7
23934551-15	2013	In JAK3- and PEPT1-expressing oocytes, peptide-induced current was blunted by the JAK3 inhibitor WHI-P154, 4-[(3"-bromo-4"-hydroxyphenyl)amino]-6,7-dimethoxyquinazoline (22 muM).	WHI P154	107-168	Janus kinase 3	Mus musculus	82-86
23934551-16	2013	In intestinal segments gly-gly generated a current which was significantly smaller in JAK3-deficient mice (jak3-/-) than in wild-type mice (jak3+/+).	Glycylglycine	23-30	Janus kinase 3	Mus musculus	107-111
23934551-16	2013	In intestinal segments gly-gly generated a current which was significantly smaller in JAK3-deficient mice (jak3-/-) than in wild-type mice (jak3+/+).	Glycylglycine	23-30	Janus kinase 3	Mus musculus	140-144
24281140-2	2013	Lack of JAK3 triggers inflammatory bowel disease, which in turn has been shown to affect intestinal activity of the epithelial Na(+) channel ENaC and thus colonic sodium absorption.	Sodium	163-169	Janus kinase 3	Mus musculus	8-12
24565406-1	2013	JAK3 inhibition with the CP-690,550 compound has an immunosuppressive potency in murine models, nonhuman primates and humans.	tofacitinib	25-31	Janus kinase 3	Mus musculus	0-4
22906008-0	2013	BD750, a benzothiazole derivative, inhibits T cell proliferation by affecting the JAK3/STAT5 signalling pathway.	benzothiazole	9-22	Janus kinase 3	Mus musculus	82-86
22906008-13	2013	CONCLUSION AND IMPLICATIONS: These data indicate that BD750 inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation.	2-(2-benzothiazoleyl)-4,5,6,7-tetrahydro-2H-indazol-3-ol	54-59	Janus kinase 3	Mus musculus	82-86
24281140-7	2013	RESULTS: The amiloride (50 microM)-induced deflection of the transepithelial potential difference was significantly lower and fecal Na(+) excretion significantly higher in jak3(-/-) mice than in jak3(+/+) mice.	Amiloride	13-22	Janus kinase 3	Mus musculus	172-176
24281140-7	2013	RESULTS: The amiloride (50 microM)-induced deflection of the transepithelial potential difference was significantly lower and fecal Na(+) excretion significantly higher in jak3(-/-) mice than in jak3(+/+) mice.	Amiloride	13-22	Janus kinase 3	Mus musculus	195-199
24281140-8	2013	Moreover, systolic arterial blood pressure was significantly lower and serum aldosterone concentration significantly higher in jak3(-/-) mice than in jak3(+/+) mice.	Aldosterone	77-88	Janus kinase 3	Mus musculus	127-131
24281140-10	2013	CONCLUSIONS: JAK3 deficiency leads to impairment of colonic ENaC activity with intestinal Na(+) loss, decrease of blood pressure, increased aldosterone release and subsequent stimulation of renal tubular Na(+) reabsorption.	Aldosterone	140-151	Janus kinase 3	Mus musculus	13-17
22728763-4	2012	As the mechanism of such preventative action has been unknown, we hypothesized that JAK3 inhibition induces generation of Tregs.	tregs	122-127	Janus kinase 3	Mus musculus	84-88
22728763-5	2012	Here, we show that the JAK3 inhibitor 4-(4"-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) suppresses proliferation of short-term cultured NOD CD4(+) T cells through induction of apoptosis, while promoting survival of a particular population of long-term cultured cells.	WHI P131	38-89	Janus kinase 3	Mus musculus	23-27
22728763-5	2012	Here, we show that the JAK3 inhibitor 4-(4"-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) suppresses proliferation of short-term cultured NOD CD4(+) T cells through induction of apoptosis, while promoting survival of a particular population of long-term cultured cells.	WHI P131	91-99	Janus kinase 3	Mus musculus	23-27
22120524-4	2012	During myogenic differentiation, treatment with the JAK3 inhibitor WHIp154 significantly increased the number of MHC-positive multinucleated myotubes and the expressions of myosin heavy chain (MHC), myogenin (MGN), MyoD, and myogenic enhancer factor 2 (MEF2).	WHI P154	67-74	Janus kinase 3	Mus musculus	52-56